Tonix Pharmaceuticals Analyst Ratings
Tonix Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/12/2023 | 591.49% | Alliance Global Partners | → $6.5 | Reiterates | → Buy |
| 04/18/2022 | -36.17% | Noble Capital Markets | → $0.6 | Initiates Coverage On | → Outperform |
| 04/18/2019 | — | Roth Capital | Upgrades | Neutral → Buy | |
| 07/27/2018 | — | B. Riley Securities | Downgrades | Buy → Neutral | |
| 07/27/2018 | — | Roth Capital | Downgrades | Buy → Neutral | |
| 06/06/2018 | 751.06% | B. Riley Securities | → $8 | Initiates Coverage On | → Buy |
| 日期 | 上/下行 | 分析師公司 | 价格目標變更 | 評級變更 | 上一頁/目前評分 |
|---|---|---|---|---|---|
| 01/12/2023 | 591.49% | 聯盟全球夥伴 | → 6.5 美元 | 重申 | → 購買 |
| 04/18/2022 | -36.17% | 貴族資本市場 | → 0.6 美元 | 啟動覆蓋範圍 | → 跑贏大市 |
| 04/18/2019 | — | 羅斯資本 | 升級 | 中性 → 購買 | |
| 2018 年 7 月 27 日 | — | B. 萊利證券 | 降級 | 購買 → 中性 | |
| 2018 年 7 月 27 日 | — | 羅斯資本 | 降級 | 購買 → 中性 | |
| 06/06/2018 | 751.06% | B. 萊利證券 | → 8 美元 | 啟動覆蓋範圍 | → 購買 |
What is the target price for Tonix Pharmaceuticals (TNXP)?
托尼克斯製藥（TNXP）的目標價格是多少？
The latest price target for Tonix Pharmaceuticals (NASDAQ: TNXP) was reported by Alliance Global Partners on January 12, 2023. The analyst firm set a price target for $6.50 expecting TNXP to rise to within 12 months (a possible 591.49% upside). 2 analyst firms have reported ratings in the last year.
聯盟全球合作夥伴於 2023 年 1 月 12 日報導了托尼克製藥（納斯達克股票代碼：TNXP）的最新價格目標。該分析師公司設定了 6.50 美元的價格目標，預計 TNXP 將在 12 個月內上升至（可能有 591.49% 的上行情況）。2 家分析師公司在去年報告了評級。
What is the most recent analyst rating for Tonix Pharmaceuticals (TNXP)?
托尼克斯製藥 (TNXP) 的最新分析師評級為何？
The latest analyst rating for Tonix Pharmaceuticals (NASDAQ: TNXP) was provided by Alliance Global Partners, and Tonix Pharmaceuticals reiterated their buy rating.
托尼克藥業（NASDAQ：TNXP）的最新分析師評級由聯盟全球合作夥伴提供，托尼克藥業重申其購買評級。
When is the next analyst rating going to be posted or updated for Tonix Pharmaceuticals (TNXP)?
托尼克斯製藥（TNXP）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tonix Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tonix Pharmaceuticals was filed on January 12, 2023 so you should expect the next rating to be made available sometime around January 12, 2024.
分析師在進行廣泛的研究後獲得了股票評級，其中包括通過公共財務報表，與 Tonix 製藥的高管和客戶交談以及收聽盈利電話會議。大多數分析師每三個月這樣做一次，因此您應該每年每家公司獲得 4 個評級。最後一個評級托尼克斯製藥提交一月 12, 2023 所以你應該期望下一個評級將在一月左右的某個時候提供 12, 2024.
Is the Analyst Rating Tonix Pharmaceuticals (TNXP) correct?
分析師評級托尼克斯製藥（TNXP）是否正確？
While ratings are subjective and will change, the latest Tonix Pharmaceuticals (TNXP) rating was a reiterated with a price target of $0.00 to $6.50. The current price Tonix Pharmaceuticals (TNXP) is trading at is $0.94, which is within the analyst's predicted range.
儘管評級是主觀的並且會發生變化，但最新的托尼克斯製藥（TNXP）評級重申，目標價格為 0.00 美元至 6.50 美元。目前的價格托尼克斯製藥（TNXP）的交易價格為 $0.94，這是分析師的預測範圍內。
譯文內容由第三人軟體翻譯。